Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

Arthritis and Rheumatology

Volumn 68, Issue 2, 2016, Pages 484-493

  Sobanski, Vincent ^a,b   Giovannelli, Jonathan ^b   Lynch, Bernadette M ^a   Schreiber, Benjamin E ^a   Nihtyanova, Svetlana I ^a   Harvey, Jennifer ^a   Handler, Clive E ^a   Denton, Christopher P ^a   Coghlan, John G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ADULT; AGE; AGE DISTRIBUTION; AGED; COHORT ANALYSIS; COMPLICATION; CONNECTIVE TISSUE DISEASE; FACTUAL DATABASE; FEMALE; HUMAN; HYPERTENSION, PULMONARY; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SYSTEMIC SCLEROSIS;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AUTOANTIBODIES; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84956714806     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39432     Document Type: Article

References (50)

1. Lefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al., Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013; 65: 2412-23.
2. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al., Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14: R213.
3. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C., Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12: 410-5.
4. Gunnarsson R, Andreassen AK, Molberg O, Lexberg AS, Time K, Dhainaut AS, et al., Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 2013; 52: 1208-13.
5. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al., Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-35.
6. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, et al., Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014; 44: 55-62.
7. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al., Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
8. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al., Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.
9. Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, et al., Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014; 44: 963-72.
10. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M., Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-9.
11. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al., Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-31.
12. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown; 1994. p. 253-6.
13. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al., Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51-9.
14. Johnson SR, Granton JT., Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20: 277-86.
15. Cappelli S, Bellando Randone S, Martinovic D, Tamas MM, Pasalic K, Allanore Y, et al., "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41: 589-98.
16. Mehra S, Walker J, Patterson K, Fritzler MJ., Autoantibodies in systemic sclerosis. Autoimmun Rev 2013; 12: 340-54.
17. Bertoli AM, Vila LM, Apte M, Fessler BJ, Bastian HM, Reveille JD, et al., Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16: 410-7.
18. Chow S, Chandran V, Fazelzad R, Johnson S., Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus 2012; 21: 353-64.
19. Lian F, Chen D, Wang Y, Ye Y, Wang X, Zhan Z, et al., Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012; 32: 1727-31.
20. Artim-Esen B, Cene E, Sahinkaya Y, Ertan S, Pehlivan O, Kamali S, et al., Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 2014; 41: 1304-10.
21. Hashimoto A, Endo H, Kondo H, Hirohata S., Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22: 272-9.
22. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al., South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
23. Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension [published erratum appears in Eur Heart J 2011;32:926]. Eur Heart J 2009; 30: 2493-537.
24. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al., ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association [published erratum appears in Circulation 2009;120:e13]. Circulation 2009; 119: 2250-94.
25. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al., Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
26. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
27. LeRoy EC, Medsger TA Jr,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
28. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al., Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
30. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
31. Gunnarsson R, Molberg O, Gilboe IM, Gran JT, PAHNOR1 Study Group. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011; 70: 1047-51.
32. Sharp GC,. Diagnostic criteria for classification of MCTD. In:, Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 23-32.
33. Alarcon-Segovia D, Villarreal M,. Classification and diagnostic criteria for mixed connective tissue disease. In:, Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 33-40.
34. Kasukawa R, Tojo T, Miyawaki S,. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In:, Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 41-7.
35. Bunn CC, Kveder T., Counterimmunoelectrophoresis and immunodiffusion for the detection of antibodies to soluble cellular antigens. In: Manual of biological markers of disease. Dordrecht (The Netherlands): Kluwer Academic; 1993. p. 1-12.
36. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al., Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S40-47.
37. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2015. URL: https://cran.r-project.org/doc/FAQ/R-FAQ.html#Citing-R.
38. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD., An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-56.
39. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al., Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94.
40. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M., Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford) 2012; 51: 1846-54.
41. Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, et al., Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2015; 74: 730-7.
42. Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP., Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406-9.
43. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al., Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011; 13: R172.
44. Steen VD., Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
45. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M., Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
46. Huang J, Li M, Tian Z, Hsieh E, Wang Q, Liu Y, et al., Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China. Clin Exp Rheumatol 2014; 32 Suppl 86: 0115-21.
47. Prabu A, Gordon C., Pulmonary arterial hypertension in SLE: what do we know? Lupus 2013; 22: 1274-85.
48. Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, et al., Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus 2014; 23: 1085-91.
49. Szodoray P, Hajas A, Kardos L, Dezso B, Soos G, Zold E, et al., Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012; 21: 1412-22.
50. Vegh J, Szodoray P, Kappelmayer J, Csipo I, Udvardy M, Lakos G, et al., Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol 2006; 64: 69-76.